



EDCTP Forum
 Partnering for Global Health Research Innovation
 and Impact in Africa
 7—10 November 2023 | Paris, France
 Celebrating EDCTP: two decades and beyond

Supported by the
 European Union



Tuesday 7 November

Cultural performance	15:45-16:00 Amphitheatre Bordeaux
Plenary session I	16:00-18:45 Amphitheatre Bordeaux
Chairs: Irene Norstedt (European Commission) and Yazdan Yazdanpanah (France)	
Welcome addresses and opening of the Eleventh EDCTP Forum	16:00-17:10
	Yazdan Yazdanpanah, ANRS Maladies Infectieuses Emergentes and Chair of the Forum Host Country Committee (France)
	Commissioner(s), European Commission (TBC)
	Bonginkosi Emmanuel Nzimande, Minister of Higher Education, Science and Innovation (South Africa) (TBC)
	Adama Diawara, Minister of Research and Higher Education (Côte d'Ivoire) (TBC)
	Tedros Adhanom Ghebreyesus, World Health Organisation (TBC)
	Maria da Graça Carvalho, Member of the European Parliament
	Matshidiso Rebecca Moeti, World Health Organisation Africa Regional Office
	Jean Kaseya, Africa Centres for Disease Control and Prevention (Africa CDC)
Keynote address EDCTP Anniversary Presentation: EDCTP 20 years and beyond – from strategy and numbers to sustainable impact	17:10-17:35
	Michael Makanga, EDCTP Association (The Netherlands)
Dr Pascoal Mocumbi keynote address: Disruptive scientific excellence and leadership for a better world	17:35-18:00
	Michel Kazatchkine, Special Advisor to the World Health Organization Regional Office for Europe (WHO/Europe)
Dr Pascoal Mocumbi Prize	18:00-18:15
Presenters:	Marcel Tanner (Switzerland) and Sonia Mocumbi (Mozambique)
Welcome message	18:15-18:30
	Henning Gädeke, Chair of the EDCTP Association and Chair of the Governing Board of the Global Health EDCTP3 Joint Undertaking (Germany)
	Sylvie Retailleau, Minister of Higher Education and Research (France)
Outstanding Female Scientist Prize	18:30-18:45
Presenter:	Sylvie Retailleau (France)
Welcome cocktail reception	18:45-21:00

Wednesday 8 November

1.1 Sponsored satellite session		08:00-09:00 Room 341
The PANdemic Preparedness PlaTform for Health and Emerging Infections' Response (PANTHER)		
Organiser(s):	PANTHER (France)	
1.1 Workshop		08:00-09:00 Room 342A
New opportunities under Global Health EDCTP3		
Organiser(s):	Global Health EDCTP3 Joint Undertaking	
Plenary session II		09:05-10:00 Amphitheatre Bordeaux
Chair: TBC		
Keynote address		09:05-09:45
Lessons learnt from COVID-19 – and other infectious diseases – positioning Africa for excellence in global health in the post-COVID-19 era		
	Salim Abdool Karim, CAPRISA (South Africa)	
EDCTP Outstanding Research Team Prize		
Presenter:	TBC	
Break		10:00-10:30
1.1 Parallel session		10:30-12:30 Room 341
Coinfections and comorbidities		
Chairs: TBC		
OA-092	Clinically relevant enantiomer specific R- and S-praziquantel pharmacokinetic drug-drug interactions with efavirenz and ritonavir: Implications for HIV and schistosomiasis co-infection Roslyn Thelingwani, African Institute of Biomedical Science and Technology (Zimbabwe)	
OA-102	Reactivation of oncogenic herpesviruses is associated with co-infections causing severe inflammatory presentations in HIV-infected patients from Gugulethu, South Africa Georgia Schafer, International Centre for Genetic Engineering and Biotechnology (ICGEB, South Africa)	
OA-223	Myocardial structure and function assessed by cardiac magnetic resonance in adolescents with perinatal-acquired HIV infection taking antiretroviral therapy Edith Majonga, Biomedical Research & Training Institute (Zimbabwe)	
OA-317	A multi-component integrated HIV/HTN care model improves hypertension screening and control in rural Uganda: A cluster randomized trial Jane Kabami, Infectious Diseases Research Collaboration (Uganda)	
OA-359	Latent tuberculosis infection among people with diabetes mellitus in Uganda and Tanzania Andrew Peter Kyazze, Makerere University (Uganda)	
OA-901	Comorbidities in children and adolescents growing up with HIV: the need to focus beyond viral suppression Rashida Ferrand, London School of Hygiene and Tropical Medicine (UK) and Biomedical Research and Training Institute (Zimbabwe)	
1.2 Parallel session		10:30-12:30 Room 342A
Emerging infectious diseases & surveillance		
Chairs: TBC		
OA-195	Spatial clustering, hotspot analysis and temporal distribution of the seventh Ebola Virus Disease outbreak in Uganda	

	George Paasi, Mbale Clinical Research Institute (Uganda)	
OA-235	Antibody responses to endemic coronaviruses in South Africa Rubina Bunjun, University of Cape Town (South Africa)	
OA-333	Kinetics of antibody in Ebola survivors following specific anti-Ebola treatment in the Democratic Republic of the Congo Antoine Nkuba Ndaye, Institut National de Recherche pour le Développement (France)	
OA-544	T cell responses to SARS-CoV-2 infection and vaccination in people living with HIV Wendy Burgers, University of Cape Town (South Africa)	
OA-652	Safety and tolerability of favipiravir for the treatment of Lassa fever: a randomized controlled open label phase II clinical trial Mirjam Groger, Bernhard Nocht Institute for Tropical Medicine (BNITM, Germany)	
OA-801	Surveillance of respiratory viruses in Gabon during the COVID-19 pandemic Georgelin Nguema Ondo, Centre de Recherches Médicales de Lambaréné (CERMEL, Gabon)	
1.3 Parallel session		10:30-12:30 Room 342B
Strengthening the ethics and regulatory framework		
Chairs: TBC		
OA-053	Using technology to build a regulatory ecosystem across Africa to help streamline regulatory approval timelines, so doing, unlocking more investment into the continent Adriaan Kruger, NuvoteQ (South Africa)	
OA-087	Research ethics committees in Mozambique: operational and functional characteristics evaluated from a self-assessment tool in 2019 Esperança Sevene, Eduardo Mondlane University (Mozambique)	
OA-442	Legislative, educational, training, institutional and social impact evaluation of the BERC-Luso project in the Portuguese-speaking African countries Maria do Céu Patrão Neves, University of the Azores, S. Miguel, Açores (Portugal)	
OA-510	Contribution of the BREEDSAFCA project to the sustainable evolution of research participants protection in Cameroon Jerome Ateudjieu, Meilleur Acces aux Soins de Sante (M.A. Sante, Cameroon)	
OA-713	Achieving the ISO9001 certification: a milestone in quality management for the national research ethics committee: the case of the Senegalese National Research Ethics Committee Samba Cor Sarr, Health Research Authority (Senegal)	
OA-721	Leveraging digital platforms to support a sustainable national research information management system for research ethics and regulation in Uganda Maxwell Otim Onapa, Busitema University (Uganda)	
Networking lunch		12:30-14:00
Meet the experts I		12:30-13:30
Poster presentations		12:45-14:00
1.2 Workshop		13:00-13:45 Room 341
WHO's Clinical Trial Resolution: Better Evidence, a Stronger Ecosystem		
Organiser:	WHO	
1.1 Scientific symposia		14:00-15:30 Room 341
Ensuring that Children with HIV in Africa survive and thrive: Celebrating the CHAPAS 4 trial partnership		
Organiser:	University College London (United Kingdom)	
Chairs:	Victor Musiime (Uganda) and Bwendo Nduna (Zambia)	
Presentations:	Optimising metabolic and bone health in Children living with HIV Mutsa Bwakura-Dangarembizi, University of Zimbabwe (Zimbabwe)	

	<p>Pharmacokinetics of drugs for second-line antiretroviral therapy among children and adolescents living with HIV Hylke Waalewijn, University of Cape Town (South Africa)</p> <p>Capacity strengthening through 'hub-and-spoke' within-country mentoring of new research centres, and training early career researchers in Africa and Europe, leveraging on a clinical trial network Veronica Mulenga, University of Zambia (Zambia)</p>	
1.2 Scientific symposia		14:00-15:30 Room 342A
Partnerships for implementation research to optimise the impact of Seasonal Malaria Chemoprevention in West and Central Africa: the OPT-SMC project		
Organiser:	Université de Thiès (Senegal)	
Chairs:	Jean Louis Ndiaye (Senegal) and Corinne Merle (Switzerland)	
Presentations:	<p>Regional partnerships for strengthening implementation research to improve access to SMC Jean-Louis Ndiaye, Université de Thiès (Senegal)</p> <p>Scaling-up of SMC in Nigeria: community perceptions and public engagement, a qualitative study in 5 States Nnenna Ogbulafor, National Malaria Elimination Programme (Nigeria)</p> <p>Barriers to SMC access in urban areas in Burkina Faso and strategies to improve uptake Christian Kompaore, Programme National de Lutte contre le Paludisme (Burkina Faso)</p> <p>Scaling-up of SMC in Guinea: adapting strategies in hard-to-reach populations Bienvenu Camara, Maferinyah Research Centre (Guinea)</p> <p>Evaluating three strategies to improve adherence to SMC in Mali Mady Cissoko/Aissata Kone, Programme National de Lutte contre le Paludisme (Mali)</p> <p>Summary and forward look for the control of seasonal malaria Fatimata Sall, Université de Thiès (Senegal)</p>	
1.3 Scientific symposia		14:00-15:30 Room 342B
A paradigm shift towards local and gender balanced leadership, promoting equitable partnerships and next generation African leaders, PAMAfrica-SINDOFO case studies		
Organiser:	Centro de Investigação em Saúde de Manhiça (CISM, Mozambique)	
Chairs:	Rella Zoleko Manego (Gabon) and Innocent Valea (Burkina Faso)	
Presentations:	<p>Capacity building, shifting the paradigm of traditional North-South collaboration practice, fostering equitable partnerships and building an African leadership Charles S Mgone, former Executive Director of EDCTP (Tanzania)</p> <p>What it takes to enhance an equitable and sustainable research in Africa, a case study of an innovative clinical trial delivery Ghyslain Mombo-Ngoma, Centre de Recherches Médicales de Lambaréné (CERMEL, Gabon)</p> <p>Career progression in clinical research for future leaders, addressing gender and opportunity challenges through advanced degree and practical training to enrich African clinical trial ecosystem Dearie Okwu, PhD student, CERMEL (Gabon) and Jessica Dalsuco, PhD student, CISM (Mozambique)</p>	
Break		15:30-16:00

Plenary session III		16:00-17:15
Chairs: TBC		
Keynote address Preventing maternal deaths, care and prevention of severe complications of pregnancy and early life: The interaction between infectious and non-communicable diseases		16:00-16:25
Claudia Hanson, Karolinska Institutet (Sweden)		
Panel: Preventing maternal deaths, care and prevention of severe complications of pregnancy and early life, addressing disparities in outcomes for women and babies from different population groups		16:25-17:15
Moderator: Marleen Temmerman, Aga Khan University (Kenya)		
Speakers:	<ul style="list-style-type: none"> • Barbara Kerstiens, European Commission • Esperança Sevene, Eduardo Mondlane University (Mozambique) • Jean-Paul Dossou, Centre de Recherche en Reproduction Humaine et en Démographie (CERRHUD, Benin) • Philippe Van de Perre, Université de Montpellier (France) 	
Break		17:15-17:45
Meet the Editors		17:45-18:45 Room 342A
Chairs: TBC		
Presenters:	<ul style="list-style-type: none"> • Zoë Mullan, Editor-in-Chief, The Lancet Global Health, Inclusion & Diversity Lead, The Lancet Group (United Kingdom) • Marco De Ambroggi, Deputy Chief Editor of Lancet Infectious Diseases (United Kingdom) • João Monteiro, Chief Editor, Nature Medicine (United States) • David Ofori-Adjei, Editor-in-Chief, Ghana Medical Journal (Ghana) 	

Thursday, 9 November

2.1 Workshop		08:00-09:00 Room 341
EDCTP Knowledge Hub		
Organiser:	The Global Health Network (United Kingdom)	
2.1 Sponsored satellite session		08:00-09:00 Room 342A
Mind the Gap: Perspectives on the pilot implementation of the first malaria vaccine		
Organiser:	PATH (United States)	
Plenary session IV		09:05-10:00 Amphitheatre Bordeaux
Chair: TBC		
Keynote address		09:05-09:35
Africa needs stronger institutions: what is making it happen?		
	Abdoulaye Djimdé, University of Bamako (Mali)	
	Audience Q&A	
EDCTP Scientific Leadership Prize		09:45-10:00
Presenter:	TBC	
Break		10:00-10:30
2.1 Parallel session		10:30-12:30 Room 341
Neglected infectious diseases: diagnosis, treatment and prevention		
Chairs: TBC		
OA-062	Improved molecular diagnosis of visceral leishmaniasis (VL) using the mini direct on blood PCR Nucleic Acid Lateral Flow Immunoassay (dbPCR-NALFIA) Henk Schallig, Academic Medical Center (Netherlands)	
OA-196	Development of a CAA/CCA duplex test for improved diagnosis of human schistosomiasis Pytsje Hoekstra, Leiden University Medical Center (Netherlands)	
OA-270	Skin diseases and their frequency patterns in skin camps in PEP4LEP implementing districts in Tanzania, preliminary results Nelly Mwangeni, Catholic University of Health and Allied Sciences (Tanzania)	
OA-445	A phase II/III multicenter randomized clinical trial evaluating the safety and efficacy of a single and three-day albendazole-ivermectin fixed-dose versus albendazole to treat soil-transmitted helminthiases Jose Muñoz, ISGLOBAL (Spain)	
OA-504	Towards an arsenic-free oral treatment for human African trypanosomiasis due to <i>T.b. rhodesiense</i>: a new tool for disease elimination Olaf Valverde Mordt, Drugs for Neglected Diseases initiative (DNDi, Switzerland)	
OA-765	Molecular diagnostic tests specificities and their contribution for HAT postelimination monitoring in Burkina Faso and Côte d'Ivoire Charlie Franck Alfred Compaoré, Institut de Recherche Pour Le Développement (Burkina Faso)	

2.2 Parallel session		10:30-12:30 Room 342A
Advances in drug development in TB and HIV		
Chairs: TBC		
OA-083	Early bactericidal activity of meropenem, ertapenem, amoxicillin/clavulanate and optimized rifampicin in pulmonary tuberculosis Caryn Upton, TASK (South Africa)	
OA-225	Optimising second line anchor drug options for children with HIV in Africa: 96-week results of the CHAPAS-4 randomised trial Abbas Lugemwa, Joint Clinical Research Centre (Uganda)	
OA-286	Plasma concentrations of first line antituberculosis drugs in infants with HIV and severe pneumonia: a pharmacokinetic sub-study of the EMPIRICAL trial Chishala Chabala, University of Zambia, School of Medicine (Zambia)	
OA-451	Spirometry, diffusion capacity, absolute lung volumes and PET/CT findings upon completion of tuberculosis treatment - preliminary findings of StatinTB/ExtendTB trial Friedrich Thienemann, University of Cape Town (South Africa)	
OA-770	Treatment outcomes of low-level viremia among adults living with HIV on dolutegravir-based first line antiretroviral therapy in Botswana Ontlametse T Bareng, Botswana Harvard AIDS Institute (Botswana)	
OA-739	High-levels of HIV drug resistance persist in ART-experienced patients post-dolutegravir rollout in KwaZulu-Natal, South Africa Aabida Khan, Department of Virology, University of KwaZulu-Natal, Durban (South Africa)	
2.3 Parallel session		10:30-12:30 Room 342B
Capacity strengthening		
Chairs: TBC		
OA-252	East and Southern African Consortium for Outbreak Epidemiology Training (ENTRANT) Emily Webb, London School of Hygiene & Tropical Medicine (LSHTM, United Kingdom)	
OA-322	Bridging the research gaps on AMR in sub-Saharan Africa - a One Health approach Rea Kobialka, Institute of Animal Hygiene and Veterinary Public Health, University of Leipzig (Germany)	
OA-345	The 1,000 global research studies challenge: developing nursing, midwifery and community health workers' research leaders to transform global healthcare Aranca De La Horra, University of Oxford (United Kingdom)	
OA-365	Capacity building as a response to emerging and re-emerging infectious diseases in Africa Peter Olupot-Olupot, Mbale Clinical Research Institute / Busitema University (Uganda)	
OA-408	Clinical trial capacity building from scratch: the WANECAM 2 experience in Niamey, Niger Abdoulaye Djimde, WANECAM 2 - University of Science, Techniques and Technologies of Bamako (Mali)	
OA-686	Advancing research on epidemic prone-pathogens: "Integrated Services for Infectious Disease Outbreak Research" (ISIDORE) Jonathan Ewbank, ERINHA (Belgium)	
Networking lunch		12:30-14:00
Meet the experts II		12:30-13:30
Poster presentations		12:45-14:00
2.2 Workshop		13:00-13:45 Room 342B
Horizon Europe: Funding opportunities for your infectious disease research projects and meet the network of European contact points for health to help you		
Organiser:	Health-NCP-Net 3.0 (HNN 3.0)	

2.4 Parallel session		14:00-16:00 Room 341
Advances in vaccines & neutralising antibodies development		
Chairs: TBC		
OA-240	Determining whether mass vaccination campaigns with fractional-dose PCV10 (PNEUMOSIL) could accelerate group protection against pneumococcal transmission in sub-Saharan Africa Issaka Soumana, Epicentre (Niger)	
OA-344	Clinical development in Burkina Faso of novel malaria vaccines based on the Pfs48/45 antigen Jordan Plieskatt, Statens Serum Institut (Denmark)	
OA-490	Safety, reactogenicity and immunogenicity of MTBVAC in newborns in a TB endemic area: a phase 2a randomized, double-blind, dose-defining trial Ingrid Murillo Jelsbak, Biofabri SLU (Spain)	
OA-498	PedMab1 clinical trial: Safety assessment of CAP256V2LS to prevent breastmilk HIV transmission in HIV-1 exposed uninfected neonates Gabriella Scarlatti, IRCCS Ospedale San Raffaele (Italy)	
OA-722	Assessment of naturally acquired humoral immunity against malaria protecting against controlled human malaria infection (CHMI) Nouhoun Barry, University of Tübingen (Germany)	
OA-779	Beneficial non-specific effects of oral polio vaccinations campaigns – did one drop save more lives than anyone could have imagined? Sebastian Nielsen, University of Southern Denmark (Denmark)	
2.5 Parallel session		14:00-16:00 Room 342A
Advancing the development and implementation of TB diagnostics		
Chairs: TBC		
OA-068	Implementation of integrated health-checks for TB-affected households in Zimbabwe Claire Calderwood, Biomedical Research and Training Institute (BRTI) & London School of Hygiene and Tropical Medicine (LSHTM, Zimbabwe)	
OA-208	Evaluating the impact of computer-assisted x-ray diagnosis and other triage tools to optimise Xpert orientated community-based active case finding for TB and COVID-19 (XACT-19) Alex Scott, Centre for Lung Infection and Immunity, University of Cape Town Lung Institute (South Africa)	
OA-272	Health system costs of decentralized TB diagnostic testing with Molbio Truenat MTB/RIF vs. hub-and-spoke GeneXpert MTB/RIF in Mozambique and Tanzania Akash Malhotra, Johns Hopkins University (United States)	
OA-464	Clinical predictors of tuberculosis in children – a prospective study in five low-middle income countries Laura Olbrich, Ludwig-Maximilians-University (Germany)	
OA-484	Improving rapid detection of 2nd line drug resistance in <i>Mycobacterium tuberculosis</i> with Xpert MTB/XDR and MolBio 2nd line Bouke De Jong, Institute of Tropical Medicine (Belgium)	
OA-724	Interrogation of an multi drug resistant tuberculosis outbreak using whole genome sequencing Elizabeth Streicher, Stellenbosch University (South Africa)	
2.6 Parallel session		14:00-16:00 Room 342B
Community engagement		
Chairs: TBC		
OA-097	Facilitators and barriers to infant HIV post-natal prophylaxis (PNP), a qualitative sub-study of the PROMISE-EPI trial in Lusaka, Zambia Anaïs Mennecier, Université de Montpellier (France)	
OA-271	Stakeholders' perspectives and willingness on use of SMS reminders and mobile money incentives to reduce loss to follow-up among presumptive TB patients in Uganda Esther Buregyeya, Makerere University School of Public Health (Uganda)	
OA-506	Working towards better guidance for studies that involve African healthy volunteers in the context of the VoIREthics initiative	

	Esperança Sevene, Eduardo Mondlane University (Mozambique)	
OA-601	Acceptability of the future introduction of intermittent preventive treatment for malaria in infants in Massinga district, Mozambique Neusa Torres, Manhiça Health Research Centre (CISM, Mozambique)	
OA-667	HIV self-testing uptake and linkage to HIV care among male fisherfolk in two fishing communities in rural Uganda: early results from the PEST4MEN study Joseph KB Matovu, Makerere University School of Public Health (Uganda)	
OA-815	A community approach to re-thinking the principles of good randomized controlled trials: informative, respectful, collaborative, feasible and well-managed Rachel Hallett, The Good Clinical Trials Collaborative (GCTC, United Kingdom)	
Break		16:00-16:30
2.1 Scientific symposia		16:30-18:00 Room 341
Making diagnostics accessible – beyond diagnostic platforms and assays		
Organiser:	Foundation for Innovative New Diagnostics (FIND, Switzerland)	
Chairs:	Katharina Kranzer (United Kingdom) and Alberto Garcia-Basteiro (Spain)	
Presentations:	<p>A diagnostic testing algorithm for inpatients living with HIV – the TB-CAPT EXULTANT trial Marta Cossa, Manhiça Health Research Centre (Mozambique)</p> <p>Real life implementation of Molbio Truenat by the National TB Program in Kenya – _what works and what does not work Immaculate Kathure, Ministry of Health (Kenya)</p> <p>Improving access to new TB diagnostic tools in Africa: bridging the research to national policy gap, to accelerate adoption and scale up Marguerite Massinga Loembe, African Society for Laboratory Medicine (ASLM, Ethiopia)</p> <p>Lessons learned from the XPEL-TB trial assessing the effectiveness and implementation of a streamlined strategy for delivery of Xpert Ultra testing Achilles Katamba, Makerere University (Uganda)</p> <p>Implementation of the Xpert MTB/XDR diagnostic test into routine laboratory algorithms in South Africa; key strategies to overcome challenges Pedro da Silva, National Priority Programmes (NPP, South Africa)</p> <p>Making diagnostics accessible – beyond diagnostic platforms and assays Panel discussion</p>	
2.2 Scientific symposia		16:30-18:00 Room 342A
From the bench to the field: contextual complexities in access and delivery of new health technologies in African health systems		
Organiser:	University of Health and Allied Sciences	
Chairs:	Jürg Utzinger (Switzerland)	
Presentations:	<p>African health research systems and Early-Stage Research and Development of innovative health technologies Olumide Ogundahunsi, University of Medical Sciences (Nigeria)</p> <p>Health system readiness and Implementation Research to support the access and delivery of new health technologies in Africa Margaret Gyapong, University of Health and Allied Sciences (Ghana)</p> <p>Capacity building in readiness for implementation and public health impact Garry Aslayan, TDR Geneva (Switzerland)</p> <p>Regulatory Frameworks and Policies to support the access and delivery of new health technologies</p>	

Cecilia Oh, UNDP Access and Delivery Partnership (Thailand)	
2.3 Scientific symposia	
16:30-18:00 Room 342B	
Working toward impactful clinical trials through collaborative research in sub-Saharan Africa: The example of the EDCTP NoEs	
Organiser:	EDCTP Regional Networks of Excellence and The Global Health Network (United Kingdom)
Chairs:	Souleymane Mboup (Senegal), Francine Ntoumi (Congo) and Bernard Kikaire (Uganda)
Presentations:	<p>Strengthening the regulatory landscape for clinical research: capacity building of NRAs and ECs in Central Africa through EDCTP funding Francine Ntoumi/Jolivet Mayela/Leonard Numfor/Gauthier Mesia, CANTAM (Congo/Cameroon)</p> <p>More than 10 years of Coordinating a Capacity Building for ICH-GCH Research Program in Sub-Saharan Africa: Experiences from East Africa Bernard Kikaire, EACCR (Uganda)</p> <p>Trials of Excellence in Southern Africa: a collaborative effort of Southern African research institutes and universities involved in Clinical Trials Rodrigues Matcheve, TESA III (Mozambique)</p> <p>Contribution of WANETAM in the research Ecosystem in West Africa Assan Jaye/Jean Pierre N'Guessan/Badou Gaye /Bai Lamin Dondeh, WANETAM (Senegal/Ivory Coast)</p> <p>The New Ecosystem for health research and data science, why, for whom and when Frank Kagoro/Elvis Temfack, TGHN (Tanzania/United Kingdom), Africa CDC (Ethiopia/Cameroon)</p> <p>Empowering Girls and Women in Science Careers in Africa: Action by NoEs NoEs</p>
Global Health EDCTP3 networking dinner	
19:00	

Friday 10 November

3.1 Sponsored satellite session		08:00-09:00 Room 341
Nothing less than health for all: Essential elements for sustainable NTD control and elimination through medical innovation (TBC)		
Organiser:	Drugs for Neglected Diseases <i>initiative</i> (DNDi, Switzerland)	
3.1 Workshop		08:00-09:00 Room 342A
More Informative Clinical Trials: The DAC-A Story		
Organiser:	Bill & Melinda Gates Foundation (United States)	
Plenary session V		09:05-10:15 Amphitheatre Bordeaux
Chair: Catherine Hankins (Canada)		
Debate: Inequalities in Global Health		09:05-10:15
Moderator:	Catherine Hankins, McGill University (Canada)	
Speakers:	<ul style="list-style-type: none"> • Agnes Binagwaho, University of Global Health Equity (Rwanda) • Margaret Gyapong, University of Health and Allied Sciences (UHAS, Ghana) • Magda Robalo Correia Silva, Institute for Global Health and Development (Guinea-Bissau) • Francisco Saúte, Director General of the Manhica Health Research Centre (CISM, Mozambique) 	
Break		10:15-10:45
3.1 Parallel session		10:45-12:30 Room 341
Partnerships		
Chairs: TBC		
OA-059	Achieving equitable leadership in Global Health partnerships: barriers experienced and strategies to improve grant funding for early and mid-career researchers in low- and middle-income countries Toyin Togun, London School of Hygiene and Tropical Medicine (LSHTM, United Kingdom)	
OA-217	Introducing a priority review voucher in the EU to encourage neglected disease product development Agustin Martin Lasanta, Deutsche Stiftung Weltbevoelkerung (DSW, Belgium)	
OA-358	Innovative access approach to translate R&D into impact for preschool-aged children suffering from schistosomiasis Beatrice Greco, ARES Trading SA, an affiliate of Merck KGaA, Darmstadt (Germany) - on behalf of Pediatric Praziquantel Consortium	
OA-533	UKCDR: enhancing coherence, collaboration, and joint action in the UK research funding landscape and beyond Maggy Heintz, UK Collaborative on Development Research (UKCDR, United Kingdom)	
OA-902	Empower African R&D stakeholders to advance equitable and sustained access to quality health products: toward policy recommendations Raffaella Ravinetto, Institute of Tropical Medicine (ITM, Belgium)	
3.2 Parallel session		10:45-12:30 Room 342A
Maternal and child health		
Chairs: TBC		
OA-058	Associations between prenatal malaria exposure, maternal antibodies at birth and malaria susceptibility during the first year of life in Burkina Faso Hamtandi Magloire Natama, Institut de Recherche en Sciences de la Sante - Unité de Recherche Clinique de Nanoro (Burkina Faso)	
OA-099	Evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women: a multi-centre, double-blind, placebo-controlled trial (MAMAH project)	

	Raquel González, Barcelona Institute for Global Health (Spain)	
OA-183	Dynamic of molecular and resistance markers prevalence of <i>Plasmodium falciparum</i> during the seasonal malaria chemoprevention campaign in school aged children in Bandiagara, Mali Karim Traoré, Malaria Research and Training Center, Université des Sciences, des Techniques et des Technologies de Bamako (USTTB, Mali)	
OA-218	Enhanced effect of seasonal malaria chemoprevention when coupled with nutrients supplementation for preventing malaria in children under five years old in Burkina Faso Paul Sondo, Institut de Recherche en Sciences de la Santé/Clinical Research Unit of Nanoro (Burkina Faso)	
OA-429	High mortality in African infants living with HIV hospitalized with severe pneumonia Bwendo Nduna, Arthur Davison Children's Hospital (Zambia)	
OA-715	Receipt of intravenous co-amoxiclav challenges eligibility screening for the PediCAP Trial in Johannesburg, South Africa David Moore, University of the Witwatersrand (South Africa)	
3.3 Parallel session		10:45-12:30 Room 342B
Capacity strengthening		
Chairs: TBC		
OA-189	Building capacity for HIV cure research in Ghana - The H-CRIS Experience George Kyei, University of Ghana (Ghana)	
OA-098	Creating a whole that is more than the sum of its parts: an emerging collaboration between clinical trial units in UK, West and East Africa Armel Zemsi, Medical Research Unit The Gambia at the London School of Hygiene & Tropical Medicine (The Gambia)	
OA-900	A bilingual training platform in data management and sharing to support open science across the EDCTP Networks of Excellence Aboubakar Soma, Centre MURAZ, National Institute of Public Health (Burkina Faso)	
OA-903	Breaking Barriers, Bridging Knowledge: Inclusion of Women in clinical research by Addressing Gender and Diversity Regional Gaps in Clinical Research Capacity in Africa Mwansa Ketty Lubeya, University Teaching Hospitals, The University of Zambia (Zambia)	
OA-904	Role of Pathogen Genomics in Public Health: Lessons from HIV and COVID-19 towards pandemic preparedness Sikhulile Moyo, Botswana Harvard AIDS Institute Partnership (Botswana)	
Networking lunch		12:30-14:00
Meet the experts III		12:30-13:30
Poster presentations		12:45-14:00
Plenary session VI		14:00-15:40 Amphitheatre Bordeaux
Chair: TBC		
Panel: Global Health EDCTP3: strategy and links with other global initiatives		14:00-15:00
Moderator: TBC		
Speakers:	<ul style="list-style-type: none"> • John Gyapong, Chair of Scientific Committee of the Global Health EDCTP3 (Ghana) • Nathalie Moll, European Federation of Pharmaceutical Industries and Associations (EFPIA, Belgium) (TBC) • Elizabeth Ekirapa Kiracho, Director at AMREF & Chair for the Advisory Council for Amref Health Africa (Uganda) (TBC) • TBC • Jean Kaseya, Africa Centres for Disease Control and Prevention (Africa CDC) 	
Closing ceremony		15:00-15:40

Chair: TBC	
	Harleen Grewal, Forum Scientific Programme Committee Chair and EDCTP Association Scientific Advisory Committee Chair (Norway)
	Michael Makanga, EDCTP Association (The Netherlands)
	Pierre Dimba, Ministry of Health, Public Hygiene and Universal Health (Côte d'Ivoire) <i>(TBC)</i>
	Tunji Alausa, Minister of State Health and Social Welfare (Nigeria)
	Anne-Claire Amprou, the French Ambassador for Global Health <i>(TBC)</i>
	Minister of Health (France) <i>(TBC)</i>